Medix Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Medix Inc.
Biocon Expects US Adalimumab Market To Consolidate, Liraglutide Plans On Course
Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.
Biocon Expects US b(Humira) Market To Consolidate, Liraglutide Plans On Course
Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.
Obesity Market Gains Weight But Better Drugs Still Needed
The US obesity market is expected to double in size over the next decade with Novo Nordisk’s Saxenda driving the growth – but real progress for the pharmaceutical sector will only come when obesity drugs offer better outcomes than non-pharma methods.
Company Information
- Industry
- Distributors
- Medical Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice